Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics.
The osmolality of contrast injected retrograde into the rat pancreatic duct did not affect the severity of the pancreatitis (Urografin, 1,300 mOsm/kg, and Hexabrix, 580 mOsm/kg). The severity of the pancreatitis induced in rats was assessed by survival rate, histologic grading, wet lung ratio, and serum levels of amylase, lipase, and trypsin-like activity. Rats with pancreatitis induced by retrograde injected Urografin, lipopolysaccharide, taurocholic acid plus enterokinase were treated with either intravenous (i.v.) FUT-175 (Nafamstat Mesilate), FUT-175 administered by retrograde pancreatic injection, i.v. terbutaline, i.v. piperacillin sodium, piperacillin sodium by retrograde pancreatic duct injection, or a combination of FUT-175 plus terbutaline and piperacillin. Survival among the rats was increased and the incidence of pancreatic infection reduced in rats treated with i.v. piperacillin or with a combination of FUT-175 plus i.v. terbutaline, plus i.v. piperacillin compared to controls.
D000208:Acute Disease; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000681:Amylases / Q000097:blood; D000818:Animals; D001550:Benzamidines; D003974:Diatrizoate Meglumine; D004765:Enteropeptidase; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use; D008049:Lipase / Q000097:blood; D008070:Lipopolysaccharides; D008297:Male; D010179:Pancreas / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use*; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013656:Taurocholic Acid; D013726:Terbutaline / Q000008:administration & dosage / Q000627:therapeutic use; D014357:Trypsin / Q000097:blood
D000318:Adrenergic beta-Agonists; D001550:Benzamidines; D006146:Guanidines; D008070:Lipopolysaccharides; D010406:Penicillins; D011480:Protease Inhibitors; D003974:Diatrizoate Meglumine; D013656:Taurocholic Acid; D008049:Lipase; D000681:Amylases; D014357:Trypsin; D004765:Enteropeptidase; D013726:Terbutaline; D010878:Piperacillin; C032855:nafamostat